Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 11/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22133207 | 0.86 | HPGD (0.51) | MEN1NPC1RAB9AKMT2AMAPT | |
| SCHEMBL4128743 | 0.86 | PDE4B (0.51) | PDE4DMAPTTDP1LMNAMAPK1 | |
| SCHEMBL4126956 | 0.84 | PDE4D (0.50) | PDE4DMAPTTDP1LMNAMAPK1 | |
| SCHEMBL4120097 | 0.84 | PDE4D (0.50) | PDE4DMEN1NPC1RAB9AKMT2A | |
| SCHEMBL8544960 | 0.83 | PDE4D (0.58) | PDE4DMEN1NPC1RAB9AKMT2A | |
| SCHEMBL4131305 | 0.83 | PDE4D (0.49) | PDE4DMEN1NPC1RAB9AKMT2A | |
| SCHEMBL10657187 | 0.81 | THRB (0.50) | PDE4DMEN1KMT2AMAPTLMNA | |
| SCHEMBL4118586 | 0.81 | HTT (0.53) | PDE4DMEN1KMT2AMAPTTDP1 | |
| SCHEMBL11680967 | 0.81 | PDE4D (0.52) | PDE4DMEN1NPC1RAB9AKMT2A | |
| SCHEMBL4133074 | 0.79 | PDE4D (0.51) | PDE4DMEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176802-A1 | ANTIDOTES TO EXOGENOUS NEUROTOXIC AGENTS | PAPADOPOULOS VASSILIOS | 2009-07-09 | — | — | US | disclosed |
| US-20060247248-A1 | Sigma-1 receptor ligand with acetylcholinesterase | SAMARITAN PHARMACEUTICALS, INC. | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247248-A1 | Sigma-1 receptor ligand with acetylcholinesterase | SIGMAR1, CHRNE, ACHE | PDE4D 2608/4885MEN1 4545/4885NPC1 694/4885 |
| US-20090176802-A1 | ANTIDOTES TO EXOGENOUS NEUROTOXIC AGENTS | INA, ACHE, NLN | PDE4D 2352/4885MEN1 2598/4885NPC1 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.